Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • DNA testing

    - PMLiVE

    UK government publishes 10 Year Health Plan for England to ‘reinvent’ NHS

    The plan’s three overarching themes are hospital to community, analogue to digital and sickness to prevention

    - PMLiVE

    BioNTech announces £1bn UK investment to boost regional R&D presence

    The UK government has also agreed to award the company a grant of up to £129m

    - PMLiVE

    UK government’s AMR study highlights importance of appropriate antibiotic use

    The UKHSA found that some bacteria are already becoming resistant to ceftazidime/avibactam

    - PMLiVE

    Prime minister unveils UK government’s plans to abolish NHS England

    The move aims to cut waiting times and free up money for front-line services

    - PMLiVE

    UK government launches ‘landmark’ AI breast cancer screening trial

    Approximately 55,000 cases of the disease are diagnosed every year in the UK

    - PMLiVE

    UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance

    The new analysis found that RSV infections lead to 640,000 antibiotic prescriptions every year

    - PMLiVE

    NHS England begins newborn screening programme to identify rare genetic conditions

    The Generation Study is aiming to screen 100,000 newborns for more than 200 diseases

    - PMLiVE

    UK government launches £400m investment programme to support clinical research

    Up to 18 clinical trial hubs will be created to accelerate the development of new drugs

    - PMLiVE

    UK government announces national RSV vaccination programme for infants and older adults

    The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK

    - PMLiVE

    UK government launches five-year national action plan for antimicrobial resistance

    It is estimated that 1.27 million global deaths in 2019 were caused by antibiotic-resistant infections

    - PMLiVE

    MHRA approves TMC Pharma’s Nulibry to treat rare genetic disease MoCD type A

    Molybdenum cofactor deficiency is estimated to affect one in 100,000 to 200,000 newborns worldwide

    - PMLiVE

    Ionis shares positive late-stage results for olezarsen in familial chylomicronaemia syndrome

    The rare genetic disease is estimated to affect up to 13 people per million in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links